Author

Jeanne Fourie

Observed names: Fourie, Jeanne, J FOURIE, J Fourie, J. Fourie

Institutions: National Health Laboratory Service, University of the Witwatersrand

Observed institutions: National Health Laboratory Service, United States Food and Drug Administration, Sunnybrook Health Science Centre, Mayo Clinic, University of Toronto, University of the Witwatersrand, University of Alabama at Birmingham, CancerCare Manitoba, UAB Medicine, Cambridge Isotope Laboratories, Inc. (United States), University of Manitoba

OpenAlex ID: A5063317308

Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians

2006 · Lori Kay Mattison, Jeanne Fourie, et al. · Clinical Cancer Research · 176

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

2010 · Michael Brave, Ann Farrell, et al. · Oncology · 135

Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine

2001 · Vural Özdemir, Werner Kalow, et al. · Journal of Clinical Psychopharmacology · 99

The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil

2006 · Lori K. Mattison, Jeanne Fourie, et al. · Clinical Cancer Research · 76

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

2004 · Adam Lee, Hany Ezzeldin, et al. · PubMed · 54

Induction of NQO1 in Cancer Cells

2004 · Asher Begleiter, Jeanne Fourie · Methods in enzymology on CD-ROM/Methods in enzymology · 53

The role of Sp1 and Sp3 in the constitutive DPYD gene expression

2006 · Xue Zhang, Lin Li, et al. · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · 34

Pharmacokinetic Changes in the Elderly

1996 · Vural Özdemir, Jeanne Fourie, et al. · Clinical Pharmacokinetics · 31

The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase

2001 · Jeanne Fourie, Curtis J. Oleschuk, et al. · Cancer Chemotherapy and Pharmacology · 24

Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity

2003 · Jeanne Fourie, Frank Guziec, et al. · Cancer Chemotherapy and Pharmacology · 16

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

2006 · Robert B Diasio, Jeanne Fourie · Drugs · 14

13 C-5-FU breath test current status and future directions: a comprehensive review

2009 · Hany H Ezzeldin, Edward P Acosta, et al. · Journal of Breath Research · 12

PDF

Prevalence and causes of thrombocytopenia in an academic state-sector laboratory in Soweto, Johannesburg, South Africa

2015 · Jenifer Leigh Vaughan, Jeanne Fourie, et al. · South African Medical Journal · 9

PDF

NMDA receptor antagonists to characterize rat renal organic cation transporter function

2002 · Jeanne Fourie, Miguel R Escobar, et al. · European Journal of Pharmacology · 7

Probing peripheral and central cholinergic system responses.

2000 · C A Naranjo, J Fourie, et al. · PubMed Central · 6

Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians

2005 · L. K. Mattison, J. Fourie, et al. · Journal of Clinical Oncology · 5

The 2-13C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-13C-uracil breath test (UraBT)

2007 · J. Fourie, L. K. Mattison, et al. · Journal of Clinical Oncology · 2

Dose dependent inhibition of uridine phosphorylase (UP) by eniluracil (EU): Was the clinical inferiority of the EU/5-fluorouracil (5-FU) phase III trials due to an unrecognized inhibition of 5-FU anabolism?

2006 · J. Fourie, V. Guarcello, et al. · Journal of Clinical Oncology · 2

Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy

2007 · V. Guarcello, J. Fourie, et al. · Journal of Clinical Oncology · 1

Hypercholesterolaemia in a group of senior South African Transport Services employees.

1988 · K Steyn, J Fourie, et al. · PubMed · 1

LBOVI-B-2Describing the catabolism of orally administered 2-13C-uracil in normal and dihydropyrimidine dehydrogenase deficient subjects using a parent/metabolite/breath model

2006 · L MATTISON, E ACOSTA, et al. · Clinical Pharmacology & Therapeutics

Functional group substitution on model bioreductive benzoquinone alkylating agents Effects on DT-diaphorase mediated mechanisms of cytotoxicity

2003 · Jeanne Fourie, Cielo Monterrosa, et al. · Proceedings of the American Association for Cancer Research Annual Meeting

Age Dependent Pupillary and Cognitive Responses to Cholinergic Drugs as a Model for Identificaton of Future Biological Markers for Alzheimer's Disease

1998 · Jeanne Fourie · Library and Archives Canada (Government of Canada)

PDF

Age Dependent Pupillary and Cognitive Responses to Cholinergic Drugs as a Model for Identificaton of Future Biological Markers for Alzheimer's Disease

1998 · Fourie, Jeanne · TSpace (University of Toronto)

PDF

Works count: 24

Citation count: 754

H-index: 12

I10-index: 12